Amphastar Pharmaceuticals, Inc. (AMPH) |
| 18.7 0.58 (3.2%) 06-04 16:00 |
| Open: | 18.28 |
| High: | 18.895 |
| Low: | 18.28 |
| Volume: | 384,773 |
| Market Cap: | 825(M) |
| PE Ratio: | 11.27 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 24.35 |
| Resistance 1: | 21.41 |
| Pivot price: | 18.24 |
| Support 1: | 16.65 |
| Support 2: | 13.85 |
| 52w High: | 31.26 |
| 52w Low: | 16.65 |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
| EPS | 1.660 |
| Book Value | 17.330 |
| PEG Ratio | 0.00 |
| Gross Profit | 7.737 |
| Profit Margin (%) | 11.00 |
| Operating Margin (%) | 7.96 |
| Return on Assets (ttm) | 5.3 |
| Return on Equity (ttm) | 10.4 |
Wed, 03 Jun 2026
Amphastar Pharmaceuticals (AMPH) director receives RSUs and options grant - Stock Titan
Wed, 03 Jun 2026
Deflin Gayle awarded RSUs and stock options at Amphastar (NASDAQ: AMPH) - Stock Titan
Wed, 03 Jun 2026
Amphastar (AMPH) director receives RSU and stock option grants - Stock Titan
Wed, 03 Jun 2026
Amphastar (AMPH) director Diane Gerst receives RSUs and stock option grant - Stock Titan
Wed, 03 Jun 2026
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow - Seeking Alpha
Tue, 02 Jun 2026
Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |